NCT05494398
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
Enrolling by Invitation
PHASE2Ages 3–13InterventionalTreatmentStanford UniversityInvestigator-initiated
~144 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:N-acetylcysteine
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)
Measured over Baseline and Week 12 of treatment
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- John Hegarty, PhD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
participation in an associated single-dose (IRB-54931, NCT04278898) or randomized, controlled trial of NAC (IRB- 68353, NCT05664789).
stable medication regimens (≥ 30 days) with no anticipated changes during the trial.
What this trial measures
- Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)Baseline and Week 12 of treatment
- Change in restricted and repetitive behaviors as measured by Children's Yale Brown Obsessive Compulsive Scale - Autism Spectrum Disorder (CYBOCS-ASD)Screening, Week 8, week 12
Higher scores on the Children's Yale Brown Obsessive Compulsive Scale - Autism Spectrum Disorder mean higher levels of restricted and repetitive behaviors (Raw Score Total Range: 0-20)